Urolitiáza u pacientů s idiopatickými střevními záněty
Autoři:
V. Teplan; M. Lukas
Působiště autorů:
IBD Clinical and Research Centre, ISCARE Lighthouse and 1st Medical Faculty of Charles University, Prague
Vyšlo v časopise:
Gastroent Hepatol 2015; 69(6): 561-569
Kategorie:
IBD: přehledová práce
doi:
https://doi.org/10.14735/amgh2015561
Souhrn
Zánětlivá onemocnění střeva jsou typicky doprovázena průjmy a malabsorpcí, což představuje predisponující faktory pro tvorbu ledvinných kamenů. Prevalence urolitiázy činí kolem 1,5– 5 %, ale u nemocných po resekci střeva 3,7– 16 %. Enterická hyperoxalurie je častou komplikací zánětlivých onemocnění střeva, ileální resekce a Roux-En-Y – gastického bypassu a je známou příčinou nefrolitiázy a nefrokalcinózy. Nadbytek oxalátů je primárně vylučován ledvinami. Zvýšené močové vylučování oxalátů vede k zvýšené saturaci moči Ca oxaláty, agregaci krystalů a vzniku urolitiázy či nefrokalcinózy. Prevence oxalátové litiázy zahrnuje vedle zvýšeného příjmu tekutin perorální podávání citrátu, magnézia, suplementu Ca, nutričně bilanční nízkooxalátové nízkotučné diety a též biologické ovlivnění střevní flóry (Oxalobacter formigenes, Bifidobacterium lactis apod.). Nové léčebné postupy u nemocných se zánětlivými onemocněními střeva zásadním způsobem změnily průběh onemocnění. Zda však tato příznivá změna ovlivní prevalenci a rizikové faktory pro tvorbu močových kamenů, není dosud známo.
Klíčová slova:
zánětlivá onemocnění střeva – urolitiáza – hyperoxalurie – střevní flora – prevence
Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.
Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.
Doručeno:
20. 11. 2015
Přijato:
27. 11. 2015
Zdroje
1. Romanko I, Lukas M, Bortlik M. New approaches in the follow-up of patients suffering from inflammatory bowel disease. Gastroent Hepatol 2015; 69(5): 441– 448. doi: 10.14735/ amgh2015441.
2. Manganiotis AN, Banner MP, Malkowicz SB. Urologic complications of Crohn’s dis-ease. Surg Clin North Am 2001; 81(1): 197– 215.
3. Banner MP. Genitourinary complications of inflammatory bowel disease. Radiol Clin North Am 1987; 25(1): 199– 209.
4. Knudsen L, Marcussen H, Fleckenstein P et al. Urolithiasis in chronic inflammatory bowel disease. Scand J Gastroenterol 1978; 13(4): 433– 436.
5. McLeod RS, Churchill DN. Ultrolithiasis complicating inflammatory bowel disease. J Urol 1993; 148(2): 974– 978.
6. Maratka Z, Nedbal J. Urolithiasis as a complication of the surgical treatment of ulcerative colitis. Gut 1964; 5: 214– 217.
7. Worcester EM. Stones due to bowel disease. In: Coe FL, Favus MJ, Pak CYC et al (eds). Kidney stones: medical and surgical management. Philadelphia: Lippincott-Raven 1996: 883– 904.
8. Deren JJ, Porush JG, Levitt MF et al. Nephrolithiasisas a complication of ulcerative colitis and regional enteritis. Ann Intern Med 1962; 56: 843– 853.
9. Robertson WG, Peacock M, Baker M et al. Studies on the prevalence and epidemiology of urinary stone disease in men in Leeds. Br J Urol 1983; 55(6): 595– 598.
10. Curhan GC, Rimm EB, Willett WC et al. Regional variation in nephrolithiasis incidence and prevalence among United States men. J Urol 1994; 151(4): 838– 841.
11. Soucie JM, Thun MJ, Coates RJ. Demographic and geographic variability of kidney stones in the United States. Kidney Int 1994; 46(3): 893– 899.
12. Parks JH, Worcester EM, O’Connor RC et al. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 2003; 63(1): 255– 265.
13. McConnell N, Campbell S, Gillanders I et al. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 2002; 89: 835– 841.
14. Ishii G, Nakajima K, Tanaka N et al. Clinical evaluation of urolithiasis in Crohn’s disease. Int J Urol 2009; 16(5): 477– 480. doi: 10.1111/ j.1442-2042.2009.02285.x.
15. Gustavsson A, Halfvarson J, Magnuson A et al. Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior tothe immunosuppressive treatment era. Am J Gastroenterol 2007; 102(11): 2513– 2519.
16. Filippi J, Allen PB, Hebuterne X et al. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets 2011; 12(10): 1440– 1447.
17. Shen B, Remzi FH, Oikonomou IK et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol 2009; 104(3): 639– 646. doi: 10.1038/ ajg.2008.78.
18. Oikonomou IK, Fazio VW, Remzi FH et al. Risk factors for anemia in patients with ileal pouch-anal anastomosis. Dis Colon Rectum 2007; 50(1): 69– 74.
19. Kuisma J, Luukkonen P, Jarvinen H et al. Risk of osteopenia after proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2002; 37(2): 171– 176.
20. Bennett RC, Hughes ES. Urinary calculi and ulcerative colitis. Br Med J 1972; 2(5812): 494– 496.
21. Knudsen L, Marcussen H, Fleckenstein P et al. Urolithiasis in chronic inflammatory bowel disease. Scand J Gastroenterol 1978; 13(4): 433– 436.
22. Gelzayd EA, Breuer RI, Kirsner JB. Nephrolithiasis in inflammatory bowel disease. Am J Dig Dis 1968; 13(12): 1027– 1034.
23. Kennedy HJ, Al-Dujaili EA, Edwards CR et al. Water and electrolyte balance in subjects with a permanent ileostomy. Gut 1983; 24(8): 702– 705.
24. Watts RW. Primary hyperoxaluria type I. QJM 1994; 87(10): 593– 600.
25. Robijn S, Hoppe B, Vervat BA et al. Hyperoxaluria: a gut-kidney axis? Kidney Int 2011; 80(11): 1146– 1158. doi: 10.1038/ ki.2011.287.
26. Streit J, Tran-Ho L, Konigsberger E. Solubility of the three calcium oxalate hydrates in sodium chloride solutions and urine-like liquors. Monatsh Chem Chem Mon 1998; 129: 1225– 1236.
27. Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am 2002; 31(4): 927– 949.
28. Earnest DL. Enteric hyperoxaluria. Adv Intern Med 1979; 24: 407– 427.
29. Williams HE. Oxalic acid and the hyperoxaluric syndromes. Kidney Int 1978; 13(5): 410– 417.
30. Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142(1): 46– 54. doi: 10.1053/ j.gastro.2011.10.001.
31. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012; 107(9): 1409– 1422. doi: 10.1038/ ajg.2012.218.
32. Aberra FN, Lichtenstein GR. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis 2005; 11(7): 685– 695.
33. Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis 2008; 14(8): 1105– 1111. doi: 10.1002/ ibd.20429.
34. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohn Colitis 2013; 7(2): 107– 112. doi: 10.1016/ j.crohns.2012.02.015.
35. Naganuma M, Kunisaki R, Yoshimura N et al. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol 2012; 48(5): 595– 600. doi: 10.1007/ s00535-012-0686-9.
36. Peyrin-Biroulet L, Pillot C, Oussalah A et al. Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience. Inflamm Bowel Dis 2012; 18(4): 697– 702. doi: 10.1002/ ibd.21777.
37. Pardi DS, Tremaine WJ, Sandborn WJ et al. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998; 93(4): 504– 514.
38. Primas C, Novacek G, Schweiger K et al. Renal insufficiency in IBD – prevalence and possible pathogenetic aspects. J Crohn Colitis 2013; 7(12): 630– 634. doi: 10.1016/ j.crohns.2013.05.001.
39. Cury D, Moss A, Schor N. Nephrolithiasis in patients with inflammatory bowel disease in the community. Int J Nephrol Renovasc Dis 2013; 6: 139– 142. doi: 10.2147/ IJNRD.S45466.
40. Huang V, Mishra R, Thanabalan R et al. Patient awareness of extraintestinal manifestations of inflammatory bowel disease. J Crohn Colitis 2013; 7(8): 318– 324. doi: 10.1016/ j.crohns.2012.11.008.
41. Kornbluth A, Hayes M, Feldman S et al. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines’ criteria. Am J Gastroenterol 2006; 101(7): 1546– 1550.
42. Mokhmalji H, Braun PM, Martinez Portillo FJ et al. Percutaneous nephrostomy versus ureteral stents for diversion of hydronephrosis caused by stones: a prospective, randomized clinical trial. J Urol 2001; 165(4): 1088– 1092.
43. Pearle MS, Pierce H, Miller GL et al. Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. J Urol 1998; 160(4): 1260– 1264.
44. Wenzler DL, Kim SP, Rosevear HM et al. Success of ureteral stents for intrinsic ureteral obstruction. J Endourol 2008; 22(2): 295– 300. doi: 10.1089/ end.2007.0201.
45. Yossepowitch O, Lifshitz DA, Dekel Y et al. Predicting the success of retrograde stenting for managing ureteral obstruction. J Urol 2001; 166(5): 1746– 1749.
46. Sammon JD, Ghani KR, Karakiewicz PI et al. Temporal trends, practice patterns, and treatment outcomes for infected upper urinary tract stones in the United States. Eur Urol 2013; 64(1): 85– 92.
47. Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med Mar 2010; 42(2): 97– 114. doi: 10.3109/ 07853890903559724.
48. Danese S, Semeraro S, Papa A et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005; 11(46): 7227– 7236.
49. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 14(30): 4819– 4831.
50. Bernstein CN, Blanchard JF, Rawsthorne Pet al. The prevalence of extraintestinal dis-eases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 1996; 96(4): 1116– 1122.
51. Ricart E, Panaccione R, Loftus EV Jr et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004; 10(3): 207– 214.
52. Mendoza JL, Lana R, Taxonera C et al. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn’s disease and ulcerative colitis. Med Clin (Barc) 2005; 125(8): 297– 300.
53. Pardi DS, Tremaine WJ, Sandborn WJ et al. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998; 93(4): 504– 514.
54. Serra I, Oller B, Mañosa M et al. Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation and outcome. J Crohns Colitis Sep 2010; 4(3): 269– 274. doi: 10.1016/ j.crohns.2009.11.009.
55. Basturk T, Ozagari A, Ozturk T et al.Crohn‘s disease and secondary amyloidosis: early complication? A case report and review of the literature. J Ren Care 2009; 35(3): 147– 150. doi: 10.1111/ j.1755-6686.2009.00106.x.
56. Peeters AJ, van den Wall Bake AW, Daha MRet al. Inflammatory bowel disease and ankylosing spondylitis associated with cutaneous vasculitis, glomerulonephritis, and circulating IgA immune complexes. Ann Rheum Dis 1990; 49(8): 638– 640.
57. Shaer AJ, Stewart LR, Cheek DE et al. IgA antiglomerular basement membrane nephritis associated with Crohn‘s disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis 2003; 41(5): 1097– 1109.
58. Kreisel W, Wolf LM, Grotz W et al. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8(5): 461– 468.
59. Lukas M, Bortlík M, Novotný A et al. Nefrotoxicita mesalazinu při dlouhodobé léčbě ulcerózní kolitidy a Crohnovy nemoci. Čes a Slov Gastroent 1999; 53(5): 135– 139.
60. Pak CY. Medical management of urinary stone disease. Nephron Clin Pract 2004; 98(2): c49– c53.
61. Kato Y, Yamaguchi S, Yachiku S et al. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis. Urology 2004; 63(1): 7– 11.
62. Massey L. Magnesium therapy for nephrolithiasis. Magnes Res 2005; 18(2): 123– 126.
63. Siener R, Schade N, Nocolay C et al. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients. J Urol 2005; 173(5): 1601– 1605.
64. Stewart CS, Duncan SH, Cave DR. Oxalobacter formigenes and its role in oxalate metabolism in the human gut. FEMS Microbiol Lett 2004; 230(1): 1– 7.
65. Delvecchio FC, Preminger GM. Medical management of stone disease. Curr Opin Urol 2003; 13(3): 229– 233.
66. Duncan SH, Richardson AJ, Kaul P et al. Oxalobacter formigenes and its potential role in human health. Appl Environ Microbiol 2002; 68(8): 3841– 3847.
67. Hoppe B, von Unruh G, Laube N et al. Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria? Urol Res 2005; 33(5): 372– 375.
68. Campieri C, Campieri M, Bertuzzi V et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 2001; 60(3): 1097– 1105.
69. Lieske JC, Goldfarb DS, De Simone C et al. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 2005; 68(3): 1244– 1249.
70. Mittal RD, Kumar R, Bid HK et al. Effect of antibiotics on Oxalobacter formigenes colonization of human gastrointestinal tract. J Endourol 2005; 19(1): 102– 106.
71. Sidhu H, Hoppe B, Hesse A et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 1998; 352(9133): 1026– 1029.
72.Troxel SA, Sidhu H, Kaul P et al. Intestinal Oxalobater formigenes colonisation in calcium oxalate stone formers and its relation to urinary oxalate. J Endourol 2003; 17(3): 173– 176.
73. Hoppe B, Leumann E, von Unruh G et al. Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front Biosci 2003; 8: e437– e443.
74. Cannon JP, Lee TA, Bolanos JT et al. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 2005; 24(1): 31– 40.
75.Vaidyanathan S, von Unruh GE, Watson ID et al. Hyperoxaluria, hypocitraturia, hypomagnesiuria, and lack of intestinal colonisation by Oxalobacter formigenes in a cervical spinal cor injury patients with suprapublic cystostomy, short bowel, and nephrolithiasis. Scienfific World J 2006; 6(6): 2403– 2410.
76. Prezioso D, Strazzullo P, Lotti T et al. Dietary tratment of urinary risk factors for renal stone formation. A review of CLU Working Group. Arch Ital Urol Androl 2015; 87(2): 105– 120. doi: 10.4081/ aiua.2015.2.105.
77. Nazzal L, Puri S, Goldfarb DS. Enteric hyperoxaluria: an important cause of end-stage kidney disease. Nephrol Dial Transplant 2015; pii: gfv005.
Štítky
Dětská gastroenterologie Gastroenterologie a hepatologie Chirurgie všeobecnáČlánek vyšel v časopise
Gastroenterologie a hepatologie
2015 Číslo 6
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Horní limit denní dávky vitaminu D: Jaké množství je ještě bezpečné?
- Cinitaprid – v Česku nová účinná látka nejen pro léčbu dysmotilitní dyspepsie
Nejčtenější v tomto čísle
- Ursodeoxycholová kyselina (Ursosan® tobolky)
- Výlučná enterální výživa – léčba první volby Crohnovy choroby u dětí
- Výsledky transplantácií pečene u slovenských detí
- Význam genetického vyšetrenia u detí s idiopatickou chronickou pankreatitídou